Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity comparison of MMR vaccines in 12-month-old infants in Iran
IRCT20201214049709N7Phase 3Recruiting
- Sponsor
- Razi Vaccine and Serum Research Institute
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of measles, mumps, and rubella vaccine in measles, mumps and rubella (2 arms), sponsored by Razi Vaccine and Serum Research Institute. Primary endpoints: Measles-specific IgG seroconversion rate, Change in measles-specific IgG level and 5 more. Started Jul 2026; status: recruiting.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on IRCT20201214049709N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201214049709N7.